PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26313445-2	2015	This Phase III study (COMMAND-4; AI444-042) evaluated the efficacy and safety of daclatasvir (DCV), a pan-genotypic HCV NS5A inhibitor, with pegylated interferon-alpha2a/ribavirin (PEG-IFN/RBV) in treatment-naive patients with HCV GT4 infection.	daclatasvir	81-92	interferon alpha 2	Homo sapiens	151-169